Evidence map›Paper›PMID 36910019›Full record

ArticleRespiratory medicine case reports2023

Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer.

Kenichiro Takeda, Hideki Miwa, Masato Kono, Ryutaro Hirama, Yuiko Oshima, Yasutaka Mochizuka, Akari Tsutsumi, Yoshihiro Miki, Dai Hashimoto, Hidenori Nakamura

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kenichiro TakedaDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Hideki MiwaDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Masato KonoDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Ryutaro HiramaDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Yuiko OshimaDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Yasutaka MochizukaDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Akari TsutsumiDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Yoshihiro MikiDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Dai HashimotoDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Hidenori NakamuraDepartment of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 75-year-old woman was admitted to our hospital with progressive dyspnea 7 months after second-line treatment with pembrolizumab for advanced non-small cell lung cancer. Chest radiography revealed hyperinflation in both lung fields, and pulmonary function tests revealed severe obstructive dysfunction without bronchodilator reversibility. There were no identifiable causes such as infections or autoimmune diseases. Therefore, bronchiolitis obliterans syndrome associated with immune checkpoint inhibitors was clinically diagnosed. Pembrolizumab was discontinued, but the respiratory dysfunction was irreversible and resulted in death. Bronchiolitis obliterans syndrome is an extremely rare but potentially severe adverse event associated with immune checkpoint inhibitor-related lung disease.

Indexed as

Bronchiolitis obliterans syndromeImmune checkpoint inhibitorImmune-related adverse eventsNon-small cell lung cancerPembrolizumab

Identifiers

PMID36910019
PMCPMC9996347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.